Clinical trials: Cholangiocarcinoma Cancer
Colorectal Cancer, Esophageal Cancer
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00012246
- Testing
- carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
This phase II trial studies how well ramucirumab works in treating patients with previously treated biliary cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced)…
- Conditions
- Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Stage III Gallbladder Cancer AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7
- Trial name
- NCT02520141
- Testing
- Laboratory Biomarker Analysis, Ramucirumab
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancer, Metastatic Cancer
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Biliary Tract Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03027284
- Testing
- Merestinib, Cisplatin, Gemcitabine
- Where
- 2 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Pancreatic Cancer, Cholangiocarcinoma
[68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer
The goal of this clinical trial is to evaluate the clinical use of [68Ga]Ga-FAPI-46 PET (positron emission tomography)/CT (computed tomography) imaging in patients with pancreatic or bile duct cancer.
- Trial name
- PANSCAN-1 (NCT05957250)
- Testing
- [68Ga]Ga-FAPI-46 PET/CT
- Where
- Netherlands
- Volunteers
- 63 people
- Sponsor
- Amsterdam UMC, location VUmc
Bile Duct Cancer, Pancreatic Cancer
Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer
In extrahepatic bile duct cancer and pancreatic cancer, we will treat postoperatively with COX2 inhibitor and assess survival rate and recurrent rate.
- Trial name
- NCT01111591
- Testing
- Cox2 inhibitor (Celecoxib)
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- Seoul National University Hospital
Advanced Solid Tumor
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Evaluating the efficacy of Neratinib tablets monotherapy in treating advanced solid tumors with HER2 mutations.
- Trial name
- CVL009-C2001 (NCT06519110)
- Testing
- Neratinib tablets
- Volunteers
- 60 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Response of Hepatic Tumors to Radioembolization
The study enrolls patients with non-resectable or borderline resectable hepatocellular carcinoma (HCC), intraheaptic choalngiocarcinoma (IHCC) or colorectal cancer metastasis.
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastasis
- Trial name
- RESRAD (NCT01775280)
- Testing
- Injection of Ytttrium-90 microspheres into the hepatic artery
- Where
- Switzerland
- Sponsor
- University of Zurich
Cholangiocellular Carcinoma
Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy
An open label, prospective, non-randomized single arm study. Combination of two treatment modalities - HAI with FUDR and systemic chemotherapy with cisplatin and gemcitabine.
- Trial name
- NCT01692704
- Testing
- Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University of Zurich
Cholangiocarcinoma
Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma
In Denmark approximately 200 new cases of cholangiocarcinoma are diagnosed every year. No standard treatment exists for patients with advanced cholangiocarcinoma, and improved systemic treatments are needed.
- Trial name
- NCT00350961
- Testing
- Gemcitabine, Oxaliplatin, Capecitabine
- Where
- 2 sites in Denmark
- Volunteers
- 39 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Ovarian Cancer, Cholangiocarcinoma Recurrent
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer…
- Conditions
- Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
- Trial name
- NCT05568680
- Testing
- SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Verismo Therapeutics
Biliary Tract Neoplasms, Liver Cancer
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
BACKGROUND: Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response.
- Conditions
- Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT02821754
- Testing
- Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Hepato Cellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma
Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)
Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato…
- Trial name
- CHOC (NCT06990659)
- Testing
- Ambulatory care, Conventional inpatient care
- Where
- 19 sites in France
- Volunteers
- 206 people
- Sponsor
- University Hospital, Angers
Intrahepatic Cholangiocarcinoma
HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin compared systemic chemotherapy of gemcitabine and cisplatin in…
- Trial name
- NCT04961970
- Testing
- oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Shi Ming
Biliary Tract Cancer, Cholangiocarcinoma
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
This study is being done to see if the investigators can improve the outcome of patients with biliary tract cancer that do not qualify for surgery.
- Trial name
- NCT06546969
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Advanced Intrahepatic Cholangiocarcinoma
Calcitriol in Advanced Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma (CCA), cancer of the bile duct, is the first cause of cancer death of the people in the northeast of Thailand. The incidence of CCA in this region is highest not only in the country but in the world.
- Trial name
- NCT01039181
- Testing
- Calcitriol
- Where
- Thailand
- Volunteers
- 28 people
- Sponsor
- National Science and Technology Development Agency, Thailand
Malignant Biliary Stenosis
Cholangioscopy or Conventional Techniques for Indeterminate Biliary Stenosis
Biliary stenosis not associated with a mass is difficult to diagnose with certainty. The diagnosis is usually based on a first-line cytological study of biliary brushing, which allows a diagnosis in 30 to 50% of cases.
- Trial name
- NCT04840537
- Testing
- endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Frederic PRAT, MD, PhD
Biliary Tract Cancer, Portal Vein Embolization
Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma
Portal vein embolization is often recommended to reduce the risk of postoperative liver failure and mortality. In this retrospective cohort study, researchers investigated the effect of portal vein embolization in patients with…
- Trial name
- NCT06222619
- Testing
- Potal vein embilization
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Seoul National University Hospital
Extrahepatic Bile Duct Cancer, Liver Cancer
Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030511
- Testing
- fluorouracil, conventional surgery, radiation therapy
- Where
- 6 sites in United States, Belgium and 1 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer, Cholangiocarcinoma
Personal Resilience Empowerment Program Study
The Personal Resilience Empowerment Program (PREP) at Hackensack Meridian Integrative Health \& Medicine was designed in Legacy Meridian to assist all selected patients with upcoming hospitalization.
- Conditions
- Lung Cancer, Cholangiocarcinoma, Pancreatic Cancer, Liver Cancer
- Trial name
- NCT03644173
- Testing
- Personal Resilience Empowerment Program including 5 sessions with health coaches
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Hackensack Meridian Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.